Cochrane · systematic review · CD009887
Stiripentol add‐on therapy for drug‐resistant focal epilepsy
Brigo, F, Igwe, SC, Bragazzi, NL · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
5
No studies
1
Included studies
NR
No studies 1 · 14.3%Ungraded 1 · 14.3%Very low 0 · 0%Low 5 · 71.4%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyAdd‐on stiripentol compared with add‐on placebo for drug‐resistant focal epilepsy
Population: people with drug‐resistant focal epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
≥ 50% reduction in seizure frequency Add‐on stiripentol vs add‐on placebo | RR 1.51 [0.81, 2.82] | 1 study · 32 participants | Low Downgraded: risk of bias, imprecision |
Seizure freedom Add‐on stiripentol vs add‐on placebo | RR 1.18 [0.31, 4.43] | 1 study · 32 participants | Low Downgraded: risk of bias, imprecision |
≥ 1 adverse effects Add‐on stiripentol vs add‐on placebo | RR 2.65 [1.08, 6.47] | 1 study · 32 participants | Low Downgraded: risk of bias, imprecision |
Neurological adverse effects Add‐on stiripentol vs add‐on placebo | RR 2.65 [0.88, 8.01] | 1 study · 32 participants | Low Downgraded: risk of bias, imprecision |
Gastrointestinal adverse effects Add‐on stiripentol vs add‐on placebo | no estimate extracted | 1 study · 32 participants | Ungraded |
Dropouts Add‐on stiripentol vs add‐on placebo | RR 0.66 [0.3, 1.47] | 1 study · 32 participants | Low Downgraded: risk of bias, imprecision |
Quality of life Add‐on stiripentol vs add‐on placebo | no estimate extracted | NR | No studies |
Stiripentol compared with placebo for drug‐resistant focal epilepsy
Population: people with drug‐resistant focal epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes* Stiripentol vs placebo | no estimate extracted | NR | No studies |
≥ 50% seizure reduction Stiripentol vs placebo | RR 1.51 [0.81, 2.82] | 1 study · 32 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Seizure freedom Stiripentol vs placebo | RR 1.18 [0.31, 4.43] | 1 study · 32 participants | Low Downgraded: risk of bias, imprecision, indirectness |
≥ 1 adverse effect Stiripentol vs placebo | RR 2.65 [1.08, 6.47] | 1 study · 32 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Neurological adverse effects Stiripentol vs placebo | RR 2.65 [0.88, 8.01] | 1 study · 32 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Gastrointestinal adverse effects Stiripentol vs placebo | RR 11.56 [0.71, 189.36] | 1 study · 32 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Dropouts Stiripentol vs placebo | RR 0.66 [0.3, 1.47] | 1 study · 32 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Stiripentol compared with placebo for focal refractory epilepsy
Population: people with focal refractory epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes* Stiripentol vs placebo | no estimate extracted | NR | No studies |
≥ 50% seizure reduction Stiripentol vs placebo | RR 1.51 [0.81, 2.82] | 1 study · 32 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Seizure freedom Stiripentol vs placebo | RR 1.18 [0.31, 4.43] | 1 study · 32 participants | Low Downgraded: risk of bias, imprecision, indirectness |
≥ 1 adverse effect Stiripentol vs placebo | RR 2.65 [1.08, 6.47] | 1 study · 32 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Neurological adverse effects Stiripentol vs placebo | RR 2.65 [0.88, 8.01] | 1 study · 32 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Gastrointestinal adverse effects Stiripentol vs placebo | RR 11.56 [0.71, 189.36] | 1 study · 32 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Dropouts Stiripentol vs placebo | RR 0.66 [0.3, 1.47] | 1 study · 32 participants | Low Downgraded: risk of bias, imprecision, indirectness |